FDA Panel Clears Merck Insomnia Drug At Lower Dose
A U.S. Food and Drug Administration advisory panel on Wednesday recommended the regulator approve Merck & Co. Inc.'s proposed insomnia drug suvorexant, but only at the lower of two suggested dosages,...To view the full article, register now.
Already a subscriber? Click here to view full article